Skip to content

Abstract B093: Combinatorial CRISPR screening reveals synthetic lethal and suppressor interactions in RTK signaling and glycosylation networks

Jul 2026 · Clinical Cancer Research · 0 citations

TL;DR

The N-glycosylation module is demonstrated as a recurrent hub of context-dependent genetic interactions and combinatorial CRISPR screening as a scalable approach for identifying therapeutic targets and resistance mechanisms in oncogene-driven cancers.

Abstract

Oncogenic contexts shape synthetic lethal vulnerabilities and suppressor interactions that underlie drug resistance mechanisms, yet this context-dependence remains poorly characterized. Combinatorial CRISPR screens offer a principled approach to surface these interactions at scale with direct implications for therapeutic targeting and drug combination strategies. Using the In4mer 4-plex Cas12a knockout platform, we screened pairwise genetic interactions across RTK signaling and glycosylation networks in oncogene-stratified cancer cells (Lin et al., BioRxiv 2025), identifying hits enriched in the glycosylation machinery. Building on these findings, focused validation screens across cancer cell lines with KRAS-, BRAF-, and EGFR-drivers confirm high-effect genetic interactions concentrated in the glycosylation module across oncogenic backgrounds, revealing both synthetic lethal dependencies and suppressor interactions. Synthetic lethal candidates linking ER stress regulation and glycosyltransferase activity were supported by dependency-expression correlations in cancer cell lines, and recurrent amplification of glycosylation machinery in patient tumors is associated with poor clinical outcomes. Preliminary cell-based validation assays further corroborate a suppressor interaction, implicating a potential resistance mechanism to EGFR inhibition. Together, these findings demonstrate the N-glycosylation module as a recurrent hub of context-dependent genetic interactions and combinatorial CRISPR screening as a scalable approach for identifying therapeutic targets and resistance mechanisms in oncogene-driven cancers. Subin Kim, Chenchu Lin, Sabriyeh Alibai, Iulia Veronica Gheorghe, Jui Hsuan Chou, Traver Hart. Combinatorial CRISPR screening reveals synthetic lethal and suppressor interactions in RTK signaling and glycosylation networks [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr B093.

View source

Similar papers

Open access Aug 2026

Dissecting context-dependent cancer vulnerabilities using Perturb-seq

It is demonstrated that integrated Perturb-seq experiments spanning diverse contexts enable hypotheses about gene function specific to tissue types or cancer subtypes – suggesting large-scale, genome-wide datasets would offer invaluable insight into the highly context-dependent nature of cancer biology.

Samuel Maffa, Isabella A. Boyle, Lie Ward et al. · 0 citations
Jul 2026

Context-dependent cancer vulnerabilities: CRISPR screening under inflammatory stress.

Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiological stresses encountered within the tumor microenvironment. In a recent issue of Nature Genetics, Cherui...

Zihan Ning, Guangchuan Wang · 0 citations
Open access Jul 2026

Unlocking Therapeutic Vulnerabilities in Leukemia with CRISPR-Based Screens 2255583

It is hypothesized that genome-wide CRISPRa screening will uncover subtype-specific genetic dependencies and drug resistance mechanisms, offering novel therapeutic insights in leukemia subtype biology, guiding future personalized treatment strategies.

Jeffrey Sullivan, Xiaozen Wen, Gabriela Flores-Vargas et al. · 0 citations
Jul 2026

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells.

Key methodological steps for achieving high-efficiency lentiviral transduction and selection are described, enabling the successful application of EPIKOL CRISPR screens in chemoresistant TNBC models.

O. Yedier-Bayram, Elif Ayca Guvener, T. Bagci-Onder · 0 citations
Jul 2026

Abstract PR006: Target discovery in rare cancers enabled by transcriptome-based virtual CRISPR screening

It is demonstrated that machine learning applied to transcriptomic data can uncover novel cancer vulnerabilities and actionable targets in individual tumors, even in the absence of functional screening, which may represent a scalable approach to advance precision oncology in rare and/or under-characterized cancer types...

Ananthan Sadagopan, Bingchen Li, Jiao Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.